Literature DB >> 27548822

Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.

Eleonora Scorletti1, Christopher D Byrne.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases from simple steatosis with hepatic lipid accumulation to end-stage liver disease with decompensated cirrhosis, liver failure and hepatocellular carcinoma. Recent data from the USA showed that in 2013, NAFLD was the second most frequent indication for liver transplantation behind hepatitis C. Since there are now effective treatments for hepatitis C and there is currently no licensed treatment for NAFLD, it has been predicted that over the next 10-15 years, NAFLD will replace hepatitis C as the most frequent indication for liver transplantation. Besides, increasing the risk of hepatocellular carcinoma and end-stage liver disease, it has recently become clear that NAFLD also increases risk of extrahepatic diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease, cardiac diseases and chronic kidney disease, to name but a few. Of each of these extrahepatic diseases, the evidence to date suggests that NAFLD is a strong risk factor for T2DM. When NAFLD occurs in combination with obesity and insulin resistance (as it frequently does), there is a marked increase in risk of incident T2DM with possible synergism occurring between liver fat accumulation, insulin resistance and obesity to further increase risk of development of T2DM. Thus, there is a reciprocal relationship between NAFLD as a risk factor for T2DM, and T2DM as a risk factor for liver disease progression in NAFLD. Moreover, recent evidence now points to the importance of perturbation of the intestinal microbiota (dysbiosis) in both T2DM and NAFLD. Consequently, there is a triangular relationship between dysbiosis and T2DM and NAFLD. This review will focus on T2DM as a key extrahepatic complication of NAFLD and will describe and discuss the triangular relationship between dysbiosis and T2DM and NAFLD and the factors and potential mechanisms underpinning this relationship.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27548822     DOI: 10.1159/000447276

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  8 in total

Review 1.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

Review 2.  Oestrogen receptor negativity in breast cancer: a cause or consequence?

Authors:  Vijaya Narasihma Reddy Gajulapalli; Vijaya Lakshmi Malisetty; Suresh Kumar Chitta; Bramanandam Manavathi
Journal:  Biosci Rep       Date:  2016-12-23       Impact factor: 3.840

3.  The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).

Authors:  Ziwen Wang; Shanshan Li; Ruifeng Wang; Liansheng Guo; Dan Xu; Tieyuan Zhang; Yifan Xu; Wenlong Wang; Min Wang; Zhongwei Gan; Xiaobing Wang
Journal:  Mol Med       Date:  2020-06-05       Impact factor: 6.354

4.  Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Min Sun Kwak; Jong In Yang; Boram Park; Seong Joon An; Joo Sung Kim
Journal:  J Korean Med Sci       Date:  2020-06-08       Impact factor: 2.153

5.  Protective effect of celastrol on type 2 diabetes mellitus with nonalcoholic fatty liver disease in mice.

Authors:  JuanJuan Sun; Hui-Juan Wang; Jun Yu; TingTing Li; YiDi Han
Journal:  Food Sci Nutr       Date:  2020-10-12       Impact factor: 2.863

Review 6.  MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.

Authors:  Nancy de Los Ángeles Segura-Azuara; Carlos Daniel Varela-Chinchilla; Plinio A Trinidad-Calderón
Journal:  Front Med (Lausanne)       Date:  2022-01-13

7.  Commercial microbiota test revealed differences in the composition of intestinal microorganisms between children with autism spectrum disorders and neurotypical peers.

Authors:  Magdalena Jendraszak; Mirosława Gałęcka; Małgorzata Kotwicka; Aleksandra Regdos; Michalina Pazgrat-Patan; Mirosław Andrusiewicz
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

Review 8.  Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.

Authors:  Ziwen Tao; Yueyue Li; Baoquan Cheng; Tao Zhou; Yanjing Gao
Journal:  J Clin Transl Hepatol       Date:  2021-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.